Shares of Akebia Therapeutics (NASDAQ: AKBA) surged 5.28% in pre-market trading on Thursday, following the release of the company's impressive first-quarter 2025 financial results. The biopharmaceutical firm significantly outperformed analyst expectations, demonstrating strong growth and a return to profitability.
Akebia reported quarterly earnings of $0.03 per share, surpassing the analyst consensus estimate of -$0.04 by an impressive 175%. This marks a substantial turnaround from the $0.09 loss per share reported in the same period last year. The company's net income reached $6.112 million, in stark contrast to the estimated loss of $10.9 million projected by analysts.
Revenue performance was equally stellar, with Akebia posting quarterly sales of $57.34 million, beating the analyst consensus estimate of $44.88 million by 27.75%. This represents a robust 75.84% increase compared to sales of $32.61 million in the same quarter of the previous year. The significant revenue growth, coupled with controlled operating expenses of $36.197 million, contributed to the company's positive bottom line. Investors are likely encouraged by Akebia's financial improvement and growth trajectory, driving the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.